التفاصيل البيبلوغرافية
| العنوان: |
Outcomes of Percutaneous Endoscopic Gastrostomy in Huntington's Disease at a Tertiary Center. |
| المؤلفون: |
Farag, Mena, Coleman, Annabelle, Knights, Harry, Murphy, Michael J., Rajagopal, Sangeerthana, Touzé, Alexiane, Shoai, Maryam, Hearst, Cara, Salanio, Desiree M., Wild, Edward J., Tabrizi, Sarah J. |
| المصدر: |
Movement Disorders Clinical Practice; Aug2024, Vol. 11 Issue 8, p998-1007, 10p |
| مصطلحات موضوعية: |
HUNTINGTON disease, SKIN infections, PUBLIC hospitals, POLYETHYLENE glycol, SURVIVAL rate, PERCUTANEOUS endoscopic gastrostomy |
| مستخلص: |
Background: Clinically assisted nutrition and hydration via percutaneous endoscopic gastrostomy (PEG) is a therapeutic option to ameliorate the difficulties associated with enhanced catabolism, weight loss, and dysphagia in Huntington's disease (HD). Objectives: The objective is to provide insights into demographics, staging (Shoulson‐Fahn), complications, weight trajectories, and survival rates in people with HD (pwHD) who underwent PEG. Methods: This retrospective study included 705 consecutive pwHD who attended our HD clinic between July 2006 and March 2024, of whom 52 underwent PEG. A control group (n = 52), comprising pwHD without PEG, were closely matched for sex, stage, age, CAG length, and disease burden score at PEG. The study was registered as a service evaluation at the National Hospital for Neurology and Neurosurgery. Results: PEG prevalence was 15.0% (n = 52/347) among manifest pwHD: 4.8% (n = 3/62) for Stage 3; 33.3% (n = 16/48) for stage 4; and 44.1% (n = 30/68) for stage 5. Commonest indications were dysphagia, weight loss, and inadequate oral intake. Complications included chest infection, tube dislodgement, and peristomal and skin infections. Modeling of weight trajectories after PEG found no difference between PEG and non‐PEG groups. Mortality rate was 34.6% (n = 18/52) in the PEG and 36.5% (n = 19/52) in the non‐PEG groups (P = 0.84). Treatment duration (until study endpoint or death) was 3.48 years (interquartile range = 1.71–6.02; range = 0.23–18.8), with 65.4% (n = 34/52) alive at the study endpoint. Conclusion: PEG in pwHD at‐risk for weight loss may help slow weight loss. Prospective studies are required to strengthen PEG decision‐making in pwHD. PEG survival was much longer than other dementias, highlighting the need to consider PEG independently in pwHD. [ABSTRACT FROM AUTHOR] |
|
Copyright of Movement Disorders Clinical Practice is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder